Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 1
2015 1
2016 2
2017 2
2019 1
2020 2
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS, Sinha MS, Avorn J. Kesselheim AS, et al. JAMA Intern Med. 2017 Nov 1;177(11):1658-1664. doi: 10.1001/jamainternmed.2017.4329. JAMA Intern Med. 2017. PMID: 28892528 Review.
The high prices of brand-name prescription drugs are a growing source of controversy in the United States. ...Overall, most new drugs receive about 12 to 16 years of market exclusivity from both kinds of monopoly protection combine …
The high prices of brand-name prescription drugs are a growing source of controversy in the United States. ...Ov …
Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017.
Rome BN, Lee CC, Gagne JJ, Kesselheim AS. Rome BN, et al. Value Health. 2021 Jun;24(6):804-811. doi: 10.1016/j.jval.2020.12.020. Epub 2021 Apr 22. Value Health. 2021. PMID: 34119078
OBJECTIVES: In the United States, brand-name prescription drugs remain expensive until market exclusivity ends and lower-cost generics become available. ...CONCLUSION: Early generic uptake decreased over the past several years. This trend …
OBJECTIVES: In the United States, brand-name prescription drugs remain expensive until market exclusiv …
Beyond The High Prices Of Prescription Drugs: A Framework To Assess Costs, Resource Allocation, And Public Funding.
Darrow JJ, Light DW. Darrow JJ, et al. Health Aff (Millwood). 2021 Feb;40(2):281-288. doi: 10.1377/hlthaff.2020.00328. Health Aff (Millwood). 2021. PMID: 33523733
New exclusivities increase prices by delaying competition, and payment programs such as Medicare Part D help guarantee that prices will be paid no matter how high they rise. ...This article provides a more comprehensive framework for legislators and scholars to use in asse …
New exclusivities increase prices by delaying competition, and payment programs such as Medicare Part D help guarantee that prices wi …
Continuing trends in U.S. brand-name and generic drug competition.
Grabowski H, Long G, Mortimer R, Bilginsoy M. Grabowski H, et al. J Med Econ. 2021 Jan-Dec;24(1):908-917. doi: 10.1080/13696998.2021.1952795. J Med Econ. 2021. PMID: 34253119 Free article.
OBJECTIVE: To provide updated evidence in a series of analyses of U.S. trends over the past two decades in key financial metrics for branded drugs: market exclusivity periods (MEPs, the time between launch and first generic entry) for new molecular ent …
OBJECTIVE: To provide updated evidence in a series of analyses of U.S. trends over the past two decades in key financial metrics for …
The unexpected consequences of generic entry.
Castanheira M, Ornaghi C, Siotis G. Castanheira M, et al. J Health Econ. 2019 Dec;68:102243. doi: 10.1016/j.jhealeco.2019.102243. Epub 2019 Oct 1. J Health Econ. 2019. PMID: 31734583
Generic drugs are sold at a fraction of the original brand price. Yet, generic entry typically produces a drop in the quantity market share of the molecule losing exclusivity. This effect is economically and statistically significant for a large dataset cover …
Generic drugs are sold at a fraction of the original brand price. Yet, generic entry typically produces a drop in the quantity mar …
Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
Lin SY, Baumann K, Zhou C, Zhou W, Cuellar AE, Xue H. Lin SY, et al. JAMA Netw Open. 2021 Nov 1;4(11):e2135371. doi: 10.1001/jamanetworkopen.2021.35371. JAMA Netw Open. 2021. PMID: 34807258 Free PMC article.
Data were analyzed from November 1, 2020, to March 30, 2021. EXPOSURES: The market entry of 5 generic statin medications (atorvastatin, rosuvastatin, simvastatin, lovastatin, and pravastatin). ...The number of brand-name statin purchases decreased by 90.9% (95% CI, 56%-98% …
Data were analyzed from November 1, 2020, to March 30, 2021. EXPOSURES: The market entry of 5 generic statin medications (atorvastati …
Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL. Mendoza RL. J Med Econ. 2020 Sep;23(9):915-922. doi: 10.1080/13696998.2020.1772797. Epub 2020 Jun 25. J Med Econ. 2020. PMID: 32432950 Free article.
AIM: Prescription drug prices in the United States are considered rather extreme. ...In fine, there remains room for opportunism among firms, particularly market incumbents, and many loopholes are unplugged by U.S. healthcare reform. ...
AIM: Prescription drug prices in the United States are considered rather extreme. ...In fine, there remains room for op …
Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis.
Rome BN, Kesselheim AS. Rome BN, et al. Clin Infect Dis. 2020 Oct 23;71(7):1671-1675. doi: 10.1093/cid/ciz1039. Clin Infect Dis. 2020. PMID: 31630159
In 2018, the REVAMP Act was proposed in Congress to reward manufacturers of certain novel antibiotics with transferrable market exclusivity vouchers. METHODS: We estimated the economic impact of this proposal by identifying antimicrobial drugs approved by the …
In 2018, the REVAMP Act was proposed in Congress to reward manufacturers of certain novel antibiotics with transferrable market ex …
The US orphan drug programme 1983-1995.
Shulman SR, Manocchia M. Shulman SR, et al. Pharmacoeconomics. 1997 Sep;12(3):312-26. doi: 10.2165/00019053-199712030-00004. Pharmacoeconomics. 1997. PMID: 10170457 Review.
This article first reviews details of the legislation and orphan drug regulations, and then provides a 13-year overview (1983-1995) of orphan drug activity in the US, including descriptive data on the designated and approved orphan drugs, their indications and sponsors. In …
This article first reviews details of the legislation and orphan drug regulations, and then provides a 13-year overview (1983-1995) of orpha …
The unintended effects of the Medicare Part D low income subsidy.
Decarolis F. Decarolis F. Health Policy. 2015 May;119(5):597-603. doi: 10.1016/j.healthpol.2015.01.008. Epub 2015 Feb 10. Health Policy. 2015. PMID: 25716285
OBJECTIVES: Medicare Part D is the voluntary program that provides insurance for prescription drugs to 37 million US elderly. This form of public insurance is delivered exclusively through a choice-based private insurance market, where Medicare pays va …
OBJECTIVES: Medicare Part D is the voluntary program that provides insurance for prescription drugs to 37 million US elderly. …
14 results